Showing results (11-20 of 50) with videos related to
Sort By:
Pageof 5
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 22, 2012
Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trialsElvin Kedhi, Gregg W Stone, Dean J Kereiakes, et al.European Heart Journal|January 14, 2015
Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score IICarlos M Campos, David van Klaveren, Vasim Farooq, et al.The Journal of Invasive Cardiology|August 6, 2013
Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stentsSaami K Yazdani, Alexander Sheehy, Masataka Nakano, et al.The American Journal of Cardiology|January 25, 2011
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial)Vivian G Ng, Alexandra J Lansky, James B Hermiller, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 19, 2011
An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT GroupHiroki Ito, Marcy Nussbaum, James B Hermiller, et al.Journal of the American College of Cardiology|April 26, 2011
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trialGregg W Stone, Ali Rizvi, Krishnankutty Sudhir, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 20, 2008
Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) GroupBruce R Brodie, Thomas Stuckey, William Downey, et al.JACC. Cardiovascular Interventions|November 21, 2009
Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) groupBruce R Brodie, Hadley Wilson, Thomas Stuckey, et al.Journal of the American College of Cardiology|December 15, 2010
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)Dean J Kereiakes, Donald E Cutlip, Robert J Applegate, et al.Circulation|November 2, 2017
Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized TrialsZiad A Ali, Runlin Gao, Takeshi Kimura, et al.Pageof 5